Real-world overall survival (OS) improvements in metastatic urothelial carcinoma (mUC) across three key therapeutic eras.
Antonio Cigliola(Vita-Salute San Raffaele University), Andrea Necchi(Vita-Salute San Raffaele University), Valentina Tateo(Vita-Salute San Raffaele University), A. Kamat(The University of Texas MD Anderson Cancer Center), Michela Piacentini(Azienda Ospedaliera Universitaria Integrata Verona), Sumanta Kumar Pal(City Of Hope National Medical Center), Nazli Dizman(The University of Texas MD Anderson Cancer Center), Chiara Mercinelli(Vita-Salute San Raffaele University), Petros Grivas(University of Washington), Philippe E. Spiess(Moffitt Cancer Center), Brigida Anna Maiorano(Vita-Salute San Raffaele University), Francesco Montorsi(Vita-Salute San Raffaele University), Shilpa Gupta(Cleveland Clinic), N. Agarwal(University of Utah), Alberto Briganti(Vita-Salute San Raffaele University), Alessandro Bertini(Vita-Salute San Raffaele University)
Cited by 1
Related Papers
Preliminary safety, pharmacokinetics and clinical activity of DFF332, an oral HIF2α inhibitor, as monotherapy in a phase 1 dose escalation study in patients with advanced clear cell renal cell carcinoma.
|Journal of Clinical Oncology|2024|9
Adjuvant Atezolizumab in Patients with Sarcomatoid Renal Cell Carcinoma: A Prespecified Subgroup Analysis of IMmotion010
|European Urology Oncology|2024|4
Zanzalintinib (XL092) plus nivolumab in non-clear cell renal cell carcinoma: The randomized phase 3 STELLAR-304 study.
|Journal of Clinical Oncology|2024|1
Genomic landscape and clinical characteristics of patients (pts) with neuroendocrine prostate cancer (NEPC) with or without aggressive variant prostate cancer characterized by molecular signature (AVPC-MS).
|Journal of Clinical Oncology|2025|1
Genomic and clinical correlates of belzutifan treatment in renal cell carcinoma (RCC): A retrospective analysis of 240 RCC patients.
|Journal of Clinical Oncology|2026|1